Glenmark gets USFDA nod to begin trials for potential cancer drug

The USFDA approval paves the way for Glenmark’s subsidiary Glenmark Specialty to proceed with a Phase 1/2, first-in-human, clinical study of GRC 54276 for the treatment of patients with advanced solid tumors and lymphomas.